EY: Post-boom biotech still has plen­ty of up­beat trends to boast about

If you just com­pare the top-line biotech num­bers for 2016 to 2015, you’d have good rea­son to de­spair. New drug ap­provals by the FDA plunged, net in­come for pub­lic biotechs cratered and to­tal cap­i­tal raised slid a stom­ach churn­ing 45%, ac­cord­ing to the fig­ures gath­ered by EY. Biotech fi­nanc­ing over­all dropped in 2016, for the first time since 2012.

So why are the an­a­lysts at EY — led by team leader Glen Gio­van­net­ti — so hap­py about last year’s per­for­mance?

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.